Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4961989 | 0.88 | ALDH1A1 (0.50) | KDM4EALDH1A1HTR2ASOAT1PPARG | |
| SCHEMBL4961660 | 0.85 | PPARG (0.45) | KDM4EALDH1A1PPARGPPARALPAR1 | |
| SCHEMBL4964263 | 0.85 | HSP90AA1 (0.44) | KDM4EALDH1A1 | |
| SCHEMBL4961998 | 0.84 | KDM4E (0.43) | KDM4EALDH1A1HTR2A | |
| SCHEMBL4964264 | 0.82 | KDM4E (0.41) | KDM4EALDH1A1HTR2APPARGPPARA | |
| SCHEMBL4964260 | 0.80 | KDM4E (0.39) | KDM4EALDH1A1HTR2ASOAT1PPARG | |
| SCHEMBL4630764 | 0.70 | SOAT1 (0.46) | KDM4EALDH1A1HTR2ASOAT1PPARG | |
| SCHEMBL4965873 | 0.70 | SOAT1 (0.46) | KDM4EALDH1A1HTR2ASOAT1PPARG | |
| SCHEMBL3963243 | 0.70 | NPC1 (0.47) | ALDH1A1HTR2ASOAT1 | |
| SCHEMBL3963129 | 0.70 | NPC1 (0.47) | ALDH1A1HTR2ASOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351858-B2 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | ASTRAZENECA AB (SE) | 2008-04-01 | — | — | US | disclosed |
| EP-1517679-B1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| US-20050222261-A1 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | ASTRAZENECA AB, R&D HEADQUARTERS, GLOBAL INTELLECTUAL PROPERTY PATENTS (SE) | 2005-10-06 | — | — | US | disclosed |
| EP-1517679-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | AstraZeneca AB (SE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000294-A1 | ORTHO-SUBSTITUTED BENZOIC ACID DERIVATIVES FOR THE TREATMENT OF INSULIN RESISTANCE | ASTRAZENECA AB (SE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222261-A1 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance | INSR, GPR119, IRS1 | KDM4E 2917/4885ALDH1A1 1463/4885HTR2A 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.